Bristol Myers Squibb Announces Positive Topline Results from Second Pivotal Phase 3 Psoriasis Study Showing Superiority of Deucravacitinib Compared to Placebo and Otezla® Biotech Investing
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 RESULTS AND RELEASES 5-YEAR PIPELINE METRICS Pharmaceutical Investing
Eversea Confirms Launch of the World's First Organic Omega-3 DHA Supplement Across USA Biotech Investing
Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT "The Spirit Molecule" Biotech Investing
Prevent Blindness and Bausch + Lomb to Launch Year-Long Video Series to Raise Awareness of Age-Related Macular Degeneration Medical Device Investing
Bristol Myers Squibb Application for Zeposia® for the Treatment of Ulcerative Colitis Accepted for Filing with Priority Review by U.S. Food and Drug Administration Biotech Investing
Merck Receives Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA® in Certain Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Pharmaceutical Investing
Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone's Vaccine Platform Technology for HIV Cure Biotech Investing
Merck Presents Results From Head-to-Head Phase 3 KEYNOTE-598 Trial Evaluating KEYTRUDA® in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer Pharmaceutical Investing
Numinus Wellness Closes Q1 2021 with Strong Cash Position and Industry Firsts Cannabis Investing News
